Droplet digital polymerase chain reaction assay for screening ofESR1mutations in 325 breast cancer specimens

    loading  Checking for direct PDF access through Ovid


Droplet digital polymerase chain reaction (ddPCR), which could perform thousands of PCRs on a nanoliter scale simultaneously, would be an attractive method to massive parallel sequencing for identifying and studying the significance of low-frequency rare mutations. Recent evidence has shown that the key potential mechanisms of the failure of aromatase inhibitors–based therapy involve identifying activating mutations affecting the ligand-binding domain of theESR1gene. Therefore, the detection ofESR1mutations may be useful as a biomarker predicting an effect of the treatment. We aimed to develop a ddPCR-based method for the sensitive detection ofESR1mutations in 325 breast cancer specimens, in which 270 primary and 55 estrogen receptor–positive (ER+) metastatic breast cancer (MBC) specimens. Our ddPCR assay could detect theESR1mutant molecules with low concentration of 0.25 copies/μL. According to the selected cutoff,ESR1mutations occurred in 7 (2.5%) of 270 primary breast cancer specimens and in 11 (20%) of 55 ER+ MBC specimens. Among the 11 MBC specimens, 5 specimens (45.5%) had the most commonESR1mutation, Y537S, 4 specimens (36.3%) each had D538G, Y537N, and Y537C. Interestingly, 2 patients had 2ESR1mutations, Y537N/D538G and Y537S/Y537C, and 2 patients had 3ESR1mutations, Y537S/Y537N/D538G. Biopsy was performed in heterochrony in 8 women twice. In 8 women, 4 women had primary breast cancer and MBC specimens and 4 women had 2 specimens when treatment was failure. Four of these 8 women acquiredESR1mutation, whereas noESR1mutation could be identified at first biopsy. ddPCR technique could be a promising tool for the next-generation sequencing-free precise detection ofESR1mutations in endocrine therapy resistant cases and may assist in determining the treatment strategy.

Related Topics

    loading  Loading Related Articles